Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Antibe Therapeutics Inc (ATBPF)

Antibe Therapeutics Inc (ATBPF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 11,423
  • Shares Outstanding, K 52,981
  • Annual Sales, $ 0 K
  • Annual Income, $ -14,730 K
  • EBIT $ -15 M
  • EBITDA $ -15 M
  • 60-Month Beta 0.51
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.60
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.25
  • Most Recent Earnings $-0.06 on 02/14/24
  • Next Earnings Date 07/04/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.10
  • Number of Estimates 1
  • High Estimate -0.10
  • Low Estimate -0.10
  • Prior Year -0.04
  • Growth Rate Est. (year over year) -150.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1113 +93.71%
on 04/02/24
0.3582 -39.81%
on 03/13/24
-0.1213 (-36.00%)
since 03/08/24
3-Month
0.1113 +93.71%
on 04/02/24
0.8122 -73.45%
on 01/09/24
-0.6214 (-74.24%)
since 01/08/24
52-Week
0.1113 +93.71%
on 04/02/24
0.8855 -75.65%
on 11/09/23
-0.2166 (-50.12%)
since 04/06/23

Most Recent Stories

More News
Antibe’s Chief Medical Officer to Present at the 2023 Precision in Clinical Trials Summit

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies to target inflammation, today announced its...

ATE.TO : 0.2950 (+13.46%)
ATBPF : 0.2156 (+13.47%)
Antibe to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies to target inflammation, today announced its...

ATE.TO : 0.2950 (+13.46%)
ATBPF : 0.2156 (+13.47%)
Antibe Provides April 2023 Corporate Update

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies to target inflammation, is pleased to provide...

ATE.TO : 0.2950 (+13.46%)
ATBPF : 0.2156 (+13.47%)
Antibe Reports Q3 2023 Interim Financial and Operating Results

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies to target inflammation, has filed its financial...

ATE.TO : 0.2950 (+13.46%)
ATBPF : 0.2156 (+13.47%)
Antibe Reports Q2 2023 Interim Financial and Operating Results

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies to target inflammation, has filed its financial...

ATE.TO : 0.2950 (+13.46%)
ATBPF : 0.2156 (+13.47%)
Antibe Closes Previously Announced Strategic Sale of Citagenix Subsidiary

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies to target inflammation, is pleased to announce...

ATE.TO : 0.2950 (+13.46%)
ATBPF : 0.2156 (+13.47%)
Antibe Provides Development Update for Otenaproxesul

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, is pleased to announce...

ATE.TO : 0.2950 (+13.46%)
ATBPF : 0.2156 (+13.47%)
Antibe Announces Results of 2022 Annual Meeting

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, is pleased to announce...

ATE.TO : 0.2950 (+13.46%)
ATBPF : 0.2156 (+13.47%)
Antibe Academic Collaborator to Present Clinical Data at PAINWeek 2022

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, is pleased to announce...

ATE.TO : 0.2950 (+13.46%)
ATBPF : 0.2156 (+13.47%)
Antibe Therapeutics Reports Q1 2023 Interim Financial and Operating Results

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, has filed its financial...

ATE.TO : 0.2950 (+13.46%)
ATBPF : 0.2156 (+13.47%)

Business Summary

Antibe Therapeutics Inc. is a biotech company with a drug platform of therapeutics in pain and inflammation. Its lead drug candidate consists of ATB-346, non-addictive drug for chronic pain and inflammation; ATB-352, for a non-addictive analgesic for treating severe acute pain, while ATB-340 is a GI-safe...

See More

Key Turning Points

3rd Resistance Point 0.3005
2nd Resistance Point 0.2729
1st Resistance Point 0.2442
Last Price 0.2156
1st Support Level 0.1879
2nd Support Level 0.1603
3rd Support Level 0.1316

See More

52-Week High 0.8855
Fibonacci 61.8% 0.5898
Fibonacci 50% 0.4984
Fibonacci 38.2% 0.4070
Last Price 0.2156
52-Week Low 0.1113

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar